Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Burkhard Micheel is active.

Publication


Featured researches published by Burkhard Micheel.


Oncogene | 2004

ST18 is a breast cancer tumor suppressor gene at human chromosome 8q11.2

Burkhard Jandrig; Susanne Seitz; Bernd Hinzmann; Wolfgang Arnold; Burkhard Micheel; Konrad Koelble; Reiner Siebert; Arnfried Schwartz; Karin Ruecker; Peter M. Schlag; Siegfried Scherneck; André Rosenthal

We have identified a gene, ST18 (suppression of tumorigenicity 18, breast carcinoma, zinc-finger protein), within a frequent imbalanced region of chromosome 8q11 as a breast cancer tumor suppressor gene. The ST18 gene encodes a zinc-finger DNA-binding protein with six fingers of the C2HC type (configuration Cys-X5-Cys-X12-His-X4-Cys) and an SMC domain. ST18 has the potential to act as transcriptional regulator. ST18 is expressed in a number of normal tissues including mammary epithelial cells although the level of expression is quite low. In breast cancer cell lines and the majority of primary breast tumors, ST18 mRNA is significantly downregulated. A 160 bp region within the promoter of the ST18 gene is hypermethylated in about 80% of the breast cancer samples and in the majority of breast cancer cell lines. The strong correlation between ST18 promoter hypermethylation and loss of ST18 expression in tumor cells suggests that this epigenetic mechanism is responsible for tumor-specific downregulation. We further show that ectopic ST18 expression in MCF-7 breast cancer cells strongly inhibits colony formation in soft agar and the formation of tumors in a xenograft mouse model.


Journal of Biotechnology | 2013

Production of functional antibody fragments in a vesicle-based eukaryotic cell-free translation system.

Marlitt Stech; Helmut Merk; Jörg A. Schenk; Walter F. M. Stöcklein; Doreen A. Wüstenhagen; Burkhard Micheel; Claus Duschl; Frank F. Bier; Stefan Kubick

Cell-free protein synthesis is of increasing interest for the rapid and high-throughput synthesis of many proteins, in particular also antibody fragments. In this study, we present a novel strategy for the production of single chain antibody fragments (scFv) in a eukaryotic in vitro translation system. This strategy comprises the cell-free expression, isolation and label-free interaction analysis of a model antibody fragment synthesized in two differently prepared insect cell lysates. These lysates contain translocationally active microsomal structures derived from the endoplasmic reticulum (ER), allowing for posttranslational modifications of cell-free synthesized proteins. Both types of these insect cell lysates enable the synthesis and translocation of scFv into ER-derived vesicles. However, only the one that has a specifically adapted redox potential yields functional active antibody fragments. We have developed a new methodology for the isolation of functional target proteins based on the translocation of cell-free produced scFv into microsomal structures and subsequent collection of protein-enriched vesicles. Antibody fragments that have been released from these vesicles are shown to be well suited for label-free binding studies. Altogether, these results show the potential of insect cell lysates for the production, purification and selection of antibody fragments in an easy-to-handle and time-saving manner.


European Journal of Cell Biology | 2010

The sarcomeric Z-disc component myopodin is a multiadapter protein that interacts with filamin and α-actinin

Anja Linnemann; Peter F.M. van der Ven; Padmanabhan Vakeel; Britta Albinus; Dirk Simonis; Gerd Bendas; Jörg A. Schenk; Burkhard Micheel; Rudolf A. Kley; Dieter O. Fürst

Here we introduce myopodin as a novel filamin C binding partner. Corroborative yeast two-hybrid and biochemical analyses indicate that the central part of myopodin that shows high homology to the closely related protein synaptopodin and that is common to all its currently known or predicted variants interacts with filamin C immunoglobulin-like domains 20-21. A detailed characterization of the previously described interaction between myopodin and alpha-actinin demonstrates for the first time that myopodin contains three independent alpha-actinin-binding sites. Newly developed myopodin-specific antibodies reveal expression at the earliest stages of in vitro differentiation of human skeletal muscle cells preceding the expression of sarcomeric alpha-actinin. Myopodin colocalizes with filamin and alpha-actinin during all stages of muscle development. By contrast, colocalization with its previously identified binding partner zyxin is restricted to early developmental stages. Genetic and cellular analyses of skeletal muscle provided direct evidence for an alternative transcriptional start site in exon three, corroborating the expression of a myopodin variant lacking the PDZ domain encoded by exons 1 and 2 in skeletal muscle. We conclude that myopodin is a multiadapter protein of the sarcomeric Z-disc that links nascent myofibrils to the sarcolemma via zyxin, and might play a role in early assembly and stabilization of the Z-disc. Mutations in FLNC, ACTN2 and several other genes encoding Z-disc-related proteins cause myopathy and cardiomyopathy. Its localization and its association with the myopathy-associated proteins filamin C and alpha-actinin make myopodin an interesting candidate for a muscle disease gene.


Journal of Molecular Recognition | 1999

Identification of peptide mimotopes for the fluorescein hapten binding of monoclonal antibody B13-DE1

V. Böttger; L.-E. Peters; Burkhard Micheel

Using 6mer and 12mer phage peptide libraries three unique phage clones were identified which specifically bind to a monoclonal anti‐FITC antibody, B13‐DE1. The two 6mer and one 12mer peptide insert sequences are clearly related to each other and contain a high proportion of hydrophobic amino acids. The peptides are bound by the antibody combining site of B13‐DE1 probably in a similar manner to FITC and represent therefore true peptidic mimics of the fluorescein hapten. No reactivity of the peptides could be demonstrated with another monoclonal anti‐fluorescein antibody or with polyclonal anti‐fluorescein antibodies. Immunization of mice with the peptides resulted in the production of antibodies cross‐reacting with all peptides but not with fluorescein. The results show that phage peptide libraries can be used to isolate mimotope peptides which can mimic low molecular weight structures seen by a specific antibody and probably other recognition molecules. Copyright


Electroanalysis | 2000

Size Exclusion Redox‐Labeled Immunoassay (SERI): A New Format for Homogeneous Amperometric Creatinine Determination

Alexander Benkert; Frieder W. Scheller; Werner Schoessler; Burkhard Micheel; Axel Warsinke

A homogeneous amperometric immunoassay for creatinine has been developed by using anti-creatinine antibodies, redox-labeled creatinine and a glassy carbon electrode covered with a semipermeable cellulose membrane with 20 kD cutoff. Creatinine from the sample competes with redox-labeled creatinine for the antigen binding sites of the antibody. Unbound conjugate passes through the membrane and is indicated at the electrode whereas antibody bound conjugate is size excluded. For redox labeling of creatinine a new labeling substance, 2-acetamido-3-chloro-1,4-naphthoquinone (AcClNQ), was used, which can be indicated electrochemically at an interference free working potential of – 200 mV (vs. Ag/AgCl). With the developed size exclusion redox-labeled immunoassay (SERI) creatinine can be determined within a range from 10 ng/mL to 100 µg/mL (0.09–900 µM).


Journal of Immunological Methods | 1994

Production of monoclonal antibodies against epitopes of the main coat protein of filamentous fd phages

Burkhard Micheel; S. Heymann; G. Scharte; V. Böttger; F. Vogel; Stefan Dübel; Frank Breitling; Melvyn Little; Olaf Behrsing

Three monoclonal antibodies (MAbs) were produced which react with epitopes of the main structural coat protein (pVIII) of filamentous fd phages as demonstrated by solid-phase fluorometric enzyme immunoassays and by immunoelectron microscopy. The antibodies are of the IgG1, IgG2a and IgG2b immunoglobulin subclasses. Since they also react with recombinant phages expressing antigen fragments in their pIII region they may be suitable reagents for the demonstration and isolation of filamentous phages used in recombinant protein technology.


Biological Chemistry | 2007

Expression of the protein phosphatase 1 inhibitor KEPI is downregulated in breast cancer cell lines and tissues and involved in the regulation of the tumor suppressor EGR1 via the MEK-ERK pathway.

Katrin Wenzel; Katjana Daskalow; Florian Herse; Susanne Seitz; Ute Zacharias; Jörg A. Schenk; Herbert Schulz; Norbert Hubner; Burkhard Micheel; Peter M. Schlag; Karl Josef Osterziel; Cemil Özcelik; Siegfried Scherneck; Burkhard Jandrig

Abstract KEPI is a protein kinase C-potentiated inhibitory protein for type 1 Ser/Thr protein phosphatases. We found no or reduced expression of KEPI in breast cancer cell lines, breast tumors and metastases in comparison to normal breast cell lines and tissues, respectively. KEPI protein expression and ubiquitous localization was detected with a newly generated antibody. Ectopic KEPI expression in MCF7 breast cancer cells induced differential expression of 95 genes, including the up-regulation of the tumor suppressors EGR1 (early growth response 1) and PTEN (phosphatase and tensin homolog), which is regulated by EGR1. We further show that the up-regulation of EGR1 in MCF7/KEPI cells is mediated by MEK-ERK signaling. The inhibition of this pathway by the MEK inhibitor UO126 led to a strong decrease in EGR1 expression in MCF7/KEPI cells. These results reveal a novel role for KEPI in the regulation of the tumor suppressor gene EGR1 via activation of the MEK-ERK MAPK pathway.


Journal of Immunological Methods | 2002

A competitive immunoassay to detect a hapten using an enzyme-labelled peptide mimotope as tracer.

Frank Sellrie; Jörg A. Schenk; Olaf Behrsing; Volker Böttger; Burkhard Micheel

Mimotope peptides-peptides which mimic the binding of a hapten to its corresponding monoclonal antibody-were conjugated to peroxidase and used in competitive immunoassay. The established immunoassay was used to quantitatively determine the concentration of hapten. As model system in all the experiments described here, we used the binding of the monoclonal antibody B13-DE1 to fluorescein and the corresponding peptide mimotope.


Analytical Methods | 2010

A homogeneous time-resolved fluoroimmunoassay (TR-FIA) using antibody mediated luminescence quenching

Frank Sellrie; Michael Beck; Niko Hildebrandt; Burkhard Micheel

The determination of low-molecular weight substances (haptens) is demonstrated with a homogeneous time-resolved immunoassay using antibody-induced luminescence quenching. Our novel assay technology uses the newly developed monoclonal antibody (G24-BA9) to quench the luminescence of europium trisbipyridine (EuTBP). We performed a competitive biotin immunoassay including an EuTBP–biotin conjugate, the anti-EuTBP antibody G24-BA9 and streptavidin as assay components. Steric hindrance allows only the binding of either G24-BA9 (to the EuTBP moiety) or streptavidin (to the biotin moiety) to the EuTBP–biotin conjugate. Addition of the analyte biotin resulted in the binding of streptavidin to biotin and a concomitant preferred binding of G24-BA9 to EuTBP–biotin. Since G24-BA9 quenches the luminescence of EuTBP within the conjugate, the luminescence signal could be used to indicate and quantify the presence of free biotin in the system. All experiments were carried out in solution in the presence of 5% serum demonstrating the possibility of using our novel assay for a very fast determination of low molecular weight substances in biological fluids.


Applied Biochemistry and Biotechnology | 1998

Production and Characterization of Monoclonal Antibodies Against Urea Derivatives

Manuela Rohde; Jörg A. Schenk; Stephan Heymann; Olaf Behrsing; Gudrun Scharte; Gerhard Kempter; Jochen Woller; Wolfgang Höhne; Axel Warsinke; Burkhard Micheel

A panel of monoclonal antibodies was generated against the ureabased haptenN-(2-N-chloroacetylaminobenzyl)-N′-4-chlorophenylurea as a tool for building up sensitive immune assays to detect urea derivatives and to screen them for catalytic antibodies (Abs). Eleven hybridomas were obtained that produced Abs reactive to the hapten. All Abs were of IgG class. Crossreactivities of the Abs to different haptens were examined, especially to a possible transition-state analog. Only four of the hybridomas (R2-DA10/F7, R2-GE7/H2, R2-HC2/A5, R2-HD6/F7) produced Abs crossreactive with the transition-state analog. From the 11 hybridomas, hybridoma B76-BF5 was chosen for further characterization. Compared to the other Abs, B76-BF5 showed the strongest binding and had a rather restricted specificity. These Abs could be used to build up a sensitive enzyme immunoassay for the detection of the hapten. All Abs were screened for crossreactivity with the pesticides monuron and diuron. No reactivity could be detected. In addition, the nucleotide sequences of the variable light and heavy chain genes of the similarly reactive Abs B76-BF5, B76-BB3, R2-DA10/F7, and R2-GA6/G3 were determined to clarify whether structure and binding specificity of these Abs showed any correlation.

Collaboration


Dive into the Burkhard Micheel's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Burkhard Jandrig

Max Delbrück Center for Molecular Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gudrun Scharte

Max Delbrück Center for Molecular Medicine

View shared research outputs
Top Co-Authors

Avatar

Ahmed Sheriff

University of Erlangen-Nuremberg

View shared research outputs
Top Co-Authors

Avatar

Birgit Vogt

University of Erlangen-Nuremberg

View shared research outputs
Researchain Logo
Decentralizing Knowledge